Veramorph, LLC
Publicly observedNorwood, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Norwood | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Veramorph, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JZD1YYDDCLP5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant10 Sept 2025Publicly observed
NIH SBIR/STTR award: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer
USD 935,236.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant10 Sept 2025Publicly observed
NIH SBIR/STTR award: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer
USD 399,985.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.